These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 37105270)

  • 41. Itch and Janus Kinase Inhibitors.
    Han Y; Woo YR; Cho SH; Lee JD; Kim HS
    Acta Derm Venereol; 2023 Feb; 103():adv00869. PubMed ID: 36789757
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Emerging systemic JAK inhibitors in the treatment of atopic dermatitis: a review of abrocitinib, baricitinib, and upadacitinib.
    Nezamololama N; Fieldhouse K; Metzger K; Gooderham M
    Drugs Context; 2020; 9():. PubMed ID: 33240390
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Evaluating topical JAK inhibitors as a treatment option for atopic dermatitis.
    Fardos MI; Singh R; Perche PO; Kelly KA; Feldman SR
    Expert Rev Clin Immunol; 2022 Mar; 18(3):221-231. PubMed ID: 34637367
    [TBL] [Abstract][Full Text] [Related]  

  • 44. JAK Inhibitor Safety Compared to Traditional Systemic Immunosuppressive Therapies.
    Daniele S; Bunick C
    J Drugs Dermatol; 2022 Dec; 21(12):1298-1303. PubMed ID: 36468956
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Abrocitinib: a potential treatment for moderate-to-severe atopic dermatitis.
    Nezamololama N; Crowley EL; Gooderham MJ; Papp K
    Expert Opin Investig Drugs; 2020 Sep; 29(9):911-917. PubMed ID: 32741227
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Delgocitinib in atopic dermatitis.
    Ho J; Molin S
    Drugs Today (Barc); 2021 Dec; 57(12):719-731. PubMed ID: 34909801
    [TBL] [Abstract][Full Text] [Related]  

  • 47. JAK Inhibitors for Atopic Dermatitis: An Update.
    He H; Guttman-Yassky E
    Am J Clin Dermatol; 2019 Apr; 20(2):181-192. PubMed ID: 30536048
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The effectiveness of Janus kinase inhibitors in treating atopic dermatitis: A systematic review and meta-analysis.
    Arora CJ; Khattak FA; Yousafzai MT; Ibitoye BM; Shumack S
    Dermatol Ther; 2020 Jul; 33(4):e13685. PubMed ID: 32463149
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Safety and Danger Considerations of Novel Treatments for Atopic Dermatitis in Context of Primary Cutaneous Lymphomas.
    Kołkowski K; Trzeciak M; Sokołowska-Wojdyło M
    Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948183
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Pruritus in atopic dermatitis-comparative evaluation of novel treatment approaches].
    Müller S; Witte F; Ständer S
    Dermatologie (Heidelb); 2022 Jul; 73(7):538-549. PubMed ID: 35925206
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study.
    Nakagawa H; Nemoto O; Igarashi A; Saeki H; Kaino H; Nagata T
    J Am Acad Dermatol; 2020 Apr; 82(4):823-831. PubMed ID: 32029304
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immunopathogenesis of Atopic Dermatitis: Focus on Interleukins as Disease Drivers and Therapeutic Targets for Novel Treatments.
    Makowska K; Nowaczyk J; Blicharz L; Waśkiel-Burnat A; Czuwara J; Olszewska M; Rudnicka L
    Int J Mol Sci; 2023 Jan; 24(1):. PubMed ID: 36614224
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy and safety of topical Janus kinase and phosphodiesterase inhibitor-4 inhibitors for the treatment of atopic dermatitis: A network meta-analysis.
    Zhang L; Du D; Wang L; Guo L; Jiang X
    J Dermatol; 2021 Dec; 48(12):1877-1883. PubMed ID: 34487567
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Deucravacitinib is an allosteric TYK2 protein kinase inhibitor FDA-approved for the treatment of psoriasis.
    Roskoski R
    Pharmacol Res; 2023 Mar; 189():106642. PubMed ID: 36754102
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The evolving atopic dermatitis management landscape.
    Sahni VN; Balogh EA; Strowd LC; Feldman SR
    Expert Opin Pharmacother; 2022 Mar; 23(4):517-526. PubMed ID: 34758685
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Abrocitinib: A New FDA-Approved Drug for Moderate-to-Severe Atopic Dermatitis.
    Perche PO; Cook MK; Feldman SR
    Ann Pharmacother; 2023 Jan; 57(1):86-98. PubMed ID: 35587593
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Emerging systemic therapies for atopic dermatitis: oral small molecules and targeted topical agents.
    Nusbaum KB; Nguyen CM; Fleischer AB
    J Dermatolog Treat; 2022 May; 33(3):1274-1278. PubMed ID: 33143506
    [TBL] [Abstract][Full Text] [Related]  

  • 58. New molecules for atopic dermatitis treatment beyond biological therapy.
    Freitas E; Torres T
    Curr Opin Allergy Clin Immunol; 2023 Jun; 23(3):210-215. PubMed ID: 37185825
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Updated Review on Treatment of Atopic Dermatitis.
    Armario-Hita JC; Galán-Gutiérrez M; Dodero-Anillo JM; Carrascosa JM; Ruiz-Villaverde R
    J Investig Allergol Clin Immunol; 2023 Jun; 33(3):158-167. PubMed ID: 37318771
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy and safety of topical JAK inhibitors in the treatment of atopic dermatitis in paediatrics and adults: A systematic review.
    Sadeghi S; Mohandesi NA
    Exp Dermatol; 2023 May; 32(5):599-610. PubMed ID: 36691705
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.